Ocera Therapeutics (OCRX) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ocera Reports Pipeline Progress and First Quarter 2015 Financial Results
April 30, 2015 8:05 AM EDTStrong Enrollment in STOP-HE Trial
Conference Call and Webcast at 10:00 a.m. ET
PALO ALTO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today provided updates on its clinical development programs of OCR-002 for the treatment of hepatic encephalopathy (HE), a severe and difficult to treat liver disorder, and reported financial results for the quarter ended March 31, 2015.
"I am pleased to report positive developments in our clinical pipeline... More
Ocera Reports Pipeline Progress and First Quarter 2015 Financial Results
April 30, 2015 8:05 AM EDTStrong Enrollment in STOP-HE Trial
Conference Call and Webcast at 10:00 a.m. ET
PALO ALTO, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq: OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today provided updates on its clinical development programs of OCR-002 for the treatment of hepatic encephalopathy (HE), a severe and difficult to treat liver disorder, and reported financial results for the quarter ended March 31, 2015.
"I am pleased to report positive developments in our clinical pipeline... More
